Azitra Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Branford, Connecticut and currently employs 12 full-time employees. The company went IPO on 2023-06-16. Azitra, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on developing advanced therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its lead product, ATR-12, is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its advanced product, ATR-04, is a genetically modified strain of S. epidermidis for treating papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, a chronic, xerotic (abnormally dry), and scaly skin disease.
Follow-Up Questions
Qui est le CEO de Azitra Inc ?
Mr. Francisco Salva est le President de Azitra Inc, il a rejoint l'entreprise depuis 2021.
Quelle est la performance du prix de l'action AZTR ?
Le prix actuel de AZTR est de $0.7638, il a increased de 0.9% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Azitra Inc ?
Azitra Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Azitra Inc ?
La capitalisation boursière actuelle de Azitra Inc est de $2.6M
Est-ce que Azitra Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 4 analystes ont établi des notations d'analystes pour Azitra Inc, y compris 2 achat fort, 4 achat, 1 maintien, 0 vente et 2 vente forte
